...
首页> 外文期刊>Journal of research in medical sciences : >Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran
【24h】

Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran

机译:伊朗伊斯法罕的幽门螺杆菌菌株对克拉霉素,甲硝唑和阿莫西林的耐药模式

获取原文
获取原文并翻译 | 示例

摘要

Helicobacter pylori (H. pylori) resistance to antibiotics has become a global problem and is an important factor in determining the outcome of treatment of infected patients. The purpose of this study was to determine the H. pylori resistance to clarithromycin, metronidazole, and amoxicillin in gastrointestinal disorders patients. Materials and Methods: In this study, a total of 260 gastric antrum biopsy specimens were collected from patients with gastrointestinal disorders who referred to Endoscopy Section of the Isfahan Hospitals. The E-test and Modified Disk Diffusion Method (MDDM) were used to verify the prevalence of antibiotic resistance in 78 H. pylori isolates to the clarithromycin, metronidazole, and amoxicillin. Results: H. pylori resistance to clarithromycin, metronidazole, and amoxicillin were 15.3, 55.1, and 6.4%, respectively. In this study, we had one multidrug resistance (MDR) isolates from patient with gastritis and peptic ulcer disease. Conclusion: Information on antibiotic susceptibility profile plays an important role in empiric antibiotic treatment and management of refractive cases. According to the results obtained in this study, H. pylori resistance to clarithromycin and metronidazole was relatively high. MDR strains are emerging and will have an effect on the combination therapy.
机译:幽门螺杆菌(H. pylori)对抗生素的耐药性已成为一个全球性问题,并且是决定感染患者治疗结果的重要因素。这项研究的目的是确定胃肠道疾病患者对幽门螺杆菌对克拉霉素,甲硝唑和阿莫西林的耐药性。资料和方法:在这项研究中,从伊斯法罕医院内窥镜科的胃肠道疾病患者中收集了总共260例胃窦活检标本。使用E检验和改良的磁盘扩散法(MDDM)来验证78幽门螺杆菌分离株对克拉霉素,甲硝唑和阿莫西林的耐药性。结果:幽门螺杆菌对克拉霉素,甲硝唑和阿莫西林的耐药性分别为15.3%,55.1%和6.4%。在这项研究中,我们从胃炎和消化性溃疡疾病患者中分离出一种多药耐药性(MDR)。结论:关于抗生素敏感性的信息在经验性抗生素治疗和屈光病例的管理中起着重要作用。根据本研究获得的结果,幽门螺杆菌对克拉霉素和甲硝唑的耐药性相对较高。 MDR菌株正在出现,并将对联合治疗产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号